198 related articles for article (PubMed ID: 15624117)
1. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier.
Ejsing TB; Linnet K
Hum Psychopharmacol; 2005 Mar; 20(2):149-53. PubMed ID: 15624117
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
Grauer MT; Uhr M
J Psychopharmacol; 2004 Mar; 18(1):66-74. PubMed ID: 15107187
[TBL] [Abstract][Full Text] [Related]
3. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
[TBL] [Abstract][Full Text] [Related]
4. The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites.
Ejsing TB; Hasselstrøm J; Linnet K
Drug Metabol Drug Interact; 2006; 21(3-4):139-62. PubMed ID: 16841511
[TBL] [Abstract][Full Text] [Related]
5. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.
Ejsing TB; Pedersen AD; Linnet K
Hum Psychopharmacol; 2005 Oct; 20(7):493-500. PubMed ID: 16118767
[TBL] [Abstract][Full Text] [Related]
7. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
8. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.
El Ela AA; Härtter S; Schmitt U; Hiemke C; Spahn-Langguth H; Langguth P
J Pharm Pharmacol; 2004 Aug; 56(8):967-75. PubMed ID: 15285840
[TBL] [Abstract][Full Text] [Related]
9. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport.
Syvänen S; Lindhe O; Palner M; Kornum BR; Rahman O; Långström B; Knudsen GM; Hammarlund-Udenaes M
Drug Metab Dispos; 2009 Mar; 37(3):635-43. PubMed ID: 19047468
[TBL] [Abstract][Full Text] [Related]
10. Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter?
Clarke G; O'Mahony SM; Cryan JF; Dinan TG
Hum Psychopharmacol; 2009 Apr; 24(3):217-23. PubMed ID: 19212940
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein restricted transport of nimodipine across blood-brain barrier.
Zhang L; Liu XD; Xie L; Wang GJ
Acta Pharmacol Sin; 2003 Sep; 24(9):903-6. PubMed ID: 12956939
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.
Kaddoumi A; Choi SU; Kinman L; Whittington D; Tsai CC; Ho RJ; Anderson BD; Unadkat JD
Drug Metab Dispos; 2007 Sep; 35(9):1459-62. PubMed ID: 17591677
[TBL] [Abstract][Full Text] [Related]
13. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat.
Letrent SP; Pollack GM; Brouwer KR; Brouwer KL
Drug Metab Dispos; 1999 Jul; 27(7):827-34. PubMed ID: 10383928
[TBL] [Abstract][Full Text] [Related]
14. P glycoprotein regulated transport of glutamate at blood brain barrier.
Liu XD; Liu GQ
Acta Pharmacol Sin; 2001 Feb; 22(2):111-6. PubMed ID: 11741514
[TBL] [Abstract][Full Text] [Related]
15. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs.
Linnet K; Ejsing TB
Eur Neuropsychopharmacol; 2008 Mar; 18(3):157-69. PubMed ID: 17683917
[TBL] [Abstract][Full Text] [Related]
16. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
Kemper EM; Cleypool C; Boogerd W; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2004 Feb; 53(2):173-8. PubMed ID: 14605863
[TBL] [Abstract][Full Text] [Related]
17. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro.
Yang HW; Liu HY; Liu X; Zhang DM; Liu YC; Liu XD; Wang GJ; Xie L
Neurosci Lett; 2008 Apr; 434(3):299-303. PubMed ID: 18313849
[TBL] [Abstract][Full Text] [Related]
18. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression.
Roberts RL; Joyce PR; Mulder RT; Begg EJ; Kennedy MA
Pharmacogenomics J; 2002; 2(3):191-6. PubMed ID: 12082591
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.
O'Brien FE; Clarke G; Fitzgerald P; Dinan TG; Griffin BT; Cryan JF
Br J Pharmacol; 2012 Jun; 166(4):1333-43. PubMed ID: 22250926
[TBL] [Abstract][Full Text] [Related]
20. Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia.
Bebawy M; Chetty M
Bioessays; 2008 Feb; 30(2):183-8. PubMed ID: 18200566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
